1. Home
  2. DINO vs PCVX Comparison

DINO vs PCVX Comparison

Compare DINO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HF Sinclair Corporation

DINO

HF Sinclair Corporation

HOLD

Current Price

$61.02

Market Cap

10.2B

Sector

Energy

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$60.69

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DINO
PCVX
Founded
1947
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
8.4B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
DINO
PCVX
Price
$61.02
$60.69
Analyst Decision
Buy
Strong Buy
Analyst Count
12
7
Target Price
$60.27
$98.33
AVG Volume (30 Days)
2.2M
1.1M
Earning Date
05-01-2026
05-06-2026
Dividend Yield
3.27%
N/A
EPS Growth
238.46
N/A
EPS
3.08
N/A
Revenue
N/A
N/A
Revenue This Year
$6.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.66
$28.09
52 Week High
$64.70
$65.00

Technical Indicators

Market Signals
Indicator
DINO
PCVX
Relative Strength Index (RSI) 57.93 61.81
Support Level $47.04 $42.30
Resistance Level $64.70 $65.00
Average True Range (ATR) 2.30 2.19
MACD -0.19 0.54
Stochastic Oscillator 52.08 92.07

Price Performance

Historical Comparison
DINO
PCVX

About DINO HF Sinclair Corporation

HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: